Tetrahydrocurcumin compositions, methods of making, and methods of using the same
US-12115138-B2 · Oct 15, 2024 · US
Treatment of fibrosis
US9937133B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9937133-B2 |
| Application number | US-201515307155-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 1, 2015 |
| Priority date | May 2, 2014 |
| Publication date | Apr 10, 2018 |
| Grant date | Apr 10, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates an aldehyde dehydrogenase inhibitor for use in the treatment or prevention of fibrosis.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating or preventing mucous membrane pemphigoid (MMP) in a patient in need thereof, the method comprising administering to said patient an aldehyde dehydrogenase inhibitor, wherein the aldehyde dehydrogenase inhibitor is tetraethylthioperoxydicarbonic diamide (disulfiram) or 4-(diethylamino)benzaldehyde (DEAB). 2. The method according to claim 1 , wherein the aldehyde dehydrogenase inhibitor is tetraethylthioperoxydicarbonic diamide (disulfiram). 3. The method according to claim 1 , wherein the aldehyde dehydrogenase inhibitor is 4-(diethylamino)benzaldehyde (DEAB). 4. The method according to claim 1 , wherein the fibrosis is ocular mucous membrane pemphigoid (OcMMP).
Assignees
Inventors
Classifications
Preparations for care of the skin · CPC title
Ophthalmic agents · CPC title
having the amino group directly attached to the aromatic ring, e.g. benzeneamine · CPC title
- A61K31/145Primary
having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155) · CPC title
Aromatic amines, i.e. where the amino group is directly linked to the aromatic nucleus · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9937133B2 cover?
- The present invention relates an aldehyde dehydrogenase inhibitor for use in the treatment or prevention of fibrosis.
- Who is the assignee on this patent?
- Ucl Business Plc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/145. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).